RecruitingPhase 1Phase 2NCT06059690

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Biologic Association Between Metabolic MR-PET and Tissue Measures of Glycolysis in Brain Tumors Visualization, Quantitation, and Targeting of Infiltrating Glioblastoma Cells With pH Sensitive Amine Chemical Exchange Saturation Transfer Magnetic Resonance Imaging-KL2TR001882

Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

50 participants

Start Date

Sep 6, 2023

Study Type

INTERVENTIONAL

Conditions

Glioblastoma Multiforme Glycolytic Index Epidermal Growth Factor Receptor

Summary

The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a combined MRI-PET scan to measure sugar metabolism (glycolysis) inside brain tumors, then comparing those measurements against what is actually found in the tumor tissue removed during surgery. The goal is to better understand glioblastoma behavior non-invasively. **You may be eligible if...** - You are over 18 years old - You have been newly diagnosed with or have a recurrent glioblastoma (aggressive brain cancer) - You are scheduled for brain surgery **You may NOT be eligible if...** - You cannot have an MRI (e.g., pacemaker, certain metal implants, or severe claustrophobia) - You have severely reduced kidney function (GFR below 30) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTpH Measurement of in vivo tissue

The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.